Abbott shares slide nearly 3% amid mixed momentum signals and volatility spike: weekly analysis

Traders Union
All News
Stocks
Abbott Laboratories slips 2.96% this week

Highlights

Shares of Abbott closed at $109.12 after declining 2.96% over the past seven days, reaching the bottom of this week’s range.
Technical signals show a steady downtrend in the short term, but longer-term structure remains intact above key moving averages.
Support sits at $108.68 and resistance at $110.16, with next week’s probable range projected at $106.78 to $111.45.

Regulatory milestones and investor inflows support sentiment this week

Abbott received FDA De Novo authorization for its Libre Duo 10 Day device on August 25, 2026, making it the first wearable FDA-cleared to monitor glucose and ketone levels, according to 24/7 Wall St. The company also obtained CE Mark approval for its Amulet 360 Left Atrial Appendage Occluder, expanding its regulatory reach in stroke prevention, as reported by Investing.com. Recent regulatory filings have highlighted new or increased holdings in ABT by several institutional investors, while Abbott maintained its quarterly dividend payout, signaling stability to shareholders.

Downside persists as momentum signals diverge near support

The daily chart shows a sustained move lower with a firm trend, as volatility over the past week registered 4.81%. Momentum signals are somewhat mixed, with the MACD in strong buy territory at 2.07, but Stochastic RSI is deep in the oversold zone, signaling potential for a near-term rebound. Nearest support is sitting at $108.68, while resistance is defined by the Ichimoku Kijun at $110.16. The overall setup suggests downside pressure persists, but the proximity to support and oversold conditions may set the stage for a bounce.

Consolidation bias dominates next week unless key levels break

Next week, the expected range is $106.78 to $111.45, with a 67% probability of an increase and 33% chance of a decrease. Base case is price consolidating between $108.68 and $110.16. A sustained break above resistance at $110.16 would open potential for further gains toward the top of the range, while a loss of $108.68 support could drive a move down toward $106.78.

Parshwa Turakhiya, analyst, sees Abbott Laboratories stock struggling to regain ground this week after sliding 3% to near $109, as bearish momentum keeps sellers in control. He notes the conflicting technical indicators: a strong MACD buy signal contrasts with a deeply oversold Stochastic RSI, suggesting the stock is vulnerable to sharp swings but could be set for a near-term rebound. Positive news flow, including FDA De Novo authorization for Libre Duo 10 Day and CE Mark approval for the Amulet 360 Left Atrial Appendage Occluder, alongside steady institutional interest and dividend stability, forms a supportive backdrop for sentiment. With support at $108.68 and resistance at $110.16 on the daily chart, Turakhiya expects consolidation between these levels, but a decisive move is likely if either boundary is broken. "With technical oversold conditions and encouraging regulatory news, I’m watching for a potential bounce toward $110.16, but remain cautious until bullish momentum is confirmed."

Earlier, analysts noted that Abbott Laboratories was in a consolidation phase with mixed short- and long-term technical signals. The latest developments—regulatory milestones and persistent institutional interest—add a new dimension, making $110.16 the key level to watch for a potential shift in trend as volatility remains elevated.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.